Novocure stock heads toward October 29 results after Japan approval

Published on 10/06/2026 at 15:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Novocure stock was last at USD 15.20 on October 5, while Q2 revenue reached USD 183.58 million. Japan approved Optune Pax ahead of October 29 results.

NVCR, JE00BYSS4X48, Illustration mit AI erstellt.

Novocure stock (ISIN JE00BYSS4X48) was last at USD 15.20 on Nasdaq on October 5, 2026, up 1.74 percent from the prior session. The next scheduled checkpoint is the companys Q3 2026 report on October 29, after Japans approval of Optune Pax for locally advanced pancreatic cancer.

October 29 brings the next test

Business Wire reported on October 1, 2026, that Novocure will publish third-quarter results on October 29, 2026, before US markets open. Management will discuss the period ended September 30, 2026, during an 8:00 a.m. EDT conference call.

The date matters because the latest reported quarter combined higher sales with a still-negative bottom line. Novocure entered the Q3 update with a market value of USD 1.8 billion and a share price 29.1 percent below its 52-week high of USD 21.45, based on the October 5 market data.

Japan expands the Optune Pax case

Japan approved Optune Pax on October 1, 2026, for adults with unresectable locally advanced pancreatic cancer alongside gemcitabine and nab-paclitaxel, according to the filed release published by StockTitan. The approval followed the Phase 3 PANOVA-3 trial, which met its primary endpoint for overall survival.

The regulatory opportunity comes with a practical risk indicator: device-related skin adverse events occurred in 76.3 percent of treated participants, while 7.7 percent experienced a Grade 3 or higher event. That safety profile leaves adoption, reimbursement and patient support central to the commercial outlook.

Revenue beat supports the valuation debate

In Q2 2026, revenue reached USD 183.58 million, up 15.6 percent from the prior year and 6.5 percent above the USD 172.44 million consensus. MarketBeat reported that the adjusted loss was USD 0.13 per share, better than the expected USD 0.33 loss, although the company remained unprofitable with a negative 21.25 percent net margin.

MarketBeat listed two Buy ratings, four Hold ratings and one Sell rating, producing a Hold consensus and an average USD 21.20 price target. The target is 39.5 percent above the October 5 price, a gap that reflects the market debate over whether revenue growth and the new pancreatic indication can translate into durable profitability.

Novocure stock stays below its yearly high

Novocure stock was last at USD 15.20 on Nasdaq at 4:00 p.m. ET on October 5, 2026. Its 52-week range was USD 9.82 to USD 21.45, with volume of 1,784,637 shares and market capitalization of USD 1.8 billion on the same date.